Background
==========

Malaria kills around one million people each year, although is a preventable and treatable infectious disease \[[@B1]\]. Because malaria is a disease that affects mostly poor and vulnerable population, it perpetuates a vicious cycle of poverty in the developing world. Malaria can be prevented, diagnosed and treated with a combination of available tools. However, it has been estimated that USD 4.2 billion is needed each year to fully fund the fight against malaria \[[@B2]\].

Drug resistant falciparum malaria is a global problem. Sulphadoxine/pyrimethamine and mefloquine resistant strains of falciparum parasites have spread quickly throughout Southeast Asia in 1980s-1990s, and the Cambodia-Thailand border is one of the endemic regions with the most severe multi-drug resistant falciparum malaria \[[@B3]-[@B6]\]. WHO has recommended the use of artemisinin combination therapy (ACT) to improve anti-malarial effectiveness and to keep the selection of drug-resistant parasites to a minimum \[[@B7]\]. Now more than 60 countries have switched to ACT for treating malaria, however, the wide-spread application of ACT has been limited by high cost \[[@B8],[@B9]\].

Dihydroartemisinin-piperaquine phosphate in a fixed-dose preparation of dihydroartemisinin 40 mg and piperaquine phosphate 320 mg has been shown to be highly effective in treating falciparum malaria with an efficacy of over 90% in China, Vietnam, and Cambodia \[[@B10]-[@B12]\]. Artemether-lumefantrine (20 mg of artemether and 120 mg of lumefantrine) is another ACT that is administered in six consecutive doses: four tablets each at 0 hours and 8 hours on the first day, then twice daily on the two consecutive days. Lumefantrine is a highly lipophilic substance, and the oral bioavailability varies considerably among individuals, and increases greatly if the drug is administered after a meal rich in fat \[[@B13]\]. This remains a limitation to the effective usage of the drug because uptake may be reduced in fasting patients.

Artemisinin-piperaquine was recently developed by Chinese scientists and has shown good efficacy and safety in a two-day treatment course \[[@B14]\]. Piperaquine is a 4-chloroquinoline (1,3-bis\[1-(7-chloro-4\'-quinolyl)-4\'-piperazinyl\]) and was used to replace chloroquine in China in 1970s-1980s. It has been shown that patients\' tolerance to piperaquine was better than to piperaquine phosphate. Additionally, piperaquine can reduce the treatment time and cost \[[@B9],[@B15]\].

The pharmacodynamics studies of artemisinin and its derivatives have shown that artemisinin (ART) and its derivatives are characterized by a quick absorption, wide distribution and quick excretion *in vivo*\[[@B16]\]. Clinical trials of ART in the treatment of uncomplicated falciparum malaria, conducted in 2002 (Li Guoqiao and others, unpublished data) showed that ART could quickly inhibit the growth of parasite at the dosage of 2 mg/kg with no significant difference in the parasite clearance time betweem ART and dihydroartemisinin (DHA) at the same dosage. DHA is the active metabolite of artemether and artesunate, which are widely used, and ART derivative must be given for 7 days for optimum cure rate if administered alone. Therefore, combining an ART derivative with another anti-malarial drug with a long half-life will shorten treatment time and is considered the treatment of choice for falciparum malaria \[[@B8],[@B17]\].

In this trial, the effectiveness and safety of the three drugs for the treatment of uncomplicated falciparum malaria were compared and evaluated for developing an optimal anti-malarial regimen.

Methods
=======

Study site and recruitment procedures
-------------------------------------

The trial was conducted in Pursat Referral Hospital, Pursat province, Cambodia. Pursat is located in the western part of the country bordering Thailand. It is located between the Tonle Sap lake and the northern end of the Cardamom Mountains. The patients for this trial came from the forest area in the Cambodia and Thailand boarder, where multi-drug resistant falciparum malaria is widespread.

The implementation of this study is according to the \"Agreement of Cambodia-China Fast Malaria Control Co-operation\" and \"National Ethics Committee for Health Research (No.03G/03NECHR)\" signed by Guangzhou University of Chinese Medicine, China, and the Ministry of Health, Kingdom of Cambodia.

Enrolment
---------

It was a prospective, open labeled, randomized controlled trial conducted on patients with microscopically confirmed symptomatic of falciparum malaria, between seven and 65 years of age. All patients with symptoms of malaria, such as fever, and who had not been administrated any anti-malarial drug, including sulphonamide, tetracycline or trimethoprim, in the previous week, were enrolled \[[@B18]\]. A standard data sheet was used to record demographic information, details of symptoms and their duration, and anti-malarial history. Clinical examination, vital signs and axillary temperature were documented. Giemsa-stained thick and thin blood films were used to confirm parasite species and parasitaemia.

Inclusion criteria: (1) patients with clinical symptoms of malaria, such as fever (axillary temperature≥37.5°C), (2) age ranged from seven to 65 years, (3) peripheral blood smears showed that falciparum malaria asexual parasite were 1,000\~100,000/μl, (4) no anti-malarial had been taken within seven days prior to the onset of symptoms or admission, including sulphonamide, tetracycline or trimethoprim.

Exclusion criteria: (1) pregnant women;(2) lactating mothers; (3) children under seven years of age, senior persons elder than 65 years of age; (4) patients with severe vomiting or diarrhoea, or other signs of severe malaria; (5) febrile diseases other than falciparum malaria; (6) exiting before the 28-day follow up and/or lack of follow-up data; (7) patients identified as re-infection by PCR were also excluded from the final cure rate and recrudescence rate calculation.

Randomization and masking
-------------------------

Patients were allocated to three treatment arms based on a pre-generated randomization list made in blocks of 20 that was produced and held independently of the field teams by a statistician. The individual allocations were kept in sealed, opaque envelopes and opened only after enrolment by the field team. Patients and clinical field workers were not blinded to the treatment arm after allocation. Microscopists were blinded to treatment allocation at follow-up examinations. Adverse events were assessed by symptom enquiry at every visit.

Drugs and regimen
-----------------

AP tablets containing 62.5 mg artemisinin (ART) and 375 mg piperaquine (PQ) per tablet were provided by Artepharm Co., Ltd., China (batch No. was 20030820). DHP tablets containing 40 mg dihydroartemisinin (DHA) and 375 mg piperaquine phosphate (PQP) were provided by Guangzhou Holleykin Pharmaceutical Co., Ltd. (batch No. was 20030301). AL tablets containing 20 mg artemether and 120 mg lumefantrine were obtained from Beijng Novartis Pharm Ltd. (batch No. was 20030822). The regimens of AP, DHP and AL were listed in Additional file [1](#S1){ref-type="supplementary-material"}, Table S1.

Follow-up
---------

At enrollment, a full physical examination, including a neurological examination and a medical history, was performed. Thick and thin blood smears were examined by microscopy, and routine haematology was performed. Drug administration was observed by study physicians. If vomiting occurred within 1 h of dosing, the medications were re-administrated. The patients were kept in the hospital for 7 days or until parasites were cleared and were followed-up weekly till D28 from the start of treatment or whenever he/she felt sick within 28 days. At each follow-up, blood smear was done via a finger prick. Blood spots were collected from those with reappearance of asexual parasitaemia. All information was recorded on a standard case record form.

Sample size
-----------

A total of 245 cases of uncomplicated malaria were enrolled for this study. The patients were separated into three random groups with 122 cases in AP group, 61 cases in DHP group and 62 cases in AL groups. And complete data from 110, 55 and 55 patients, respectively, were obtained and analyzed.

Laboratory tests and outcome measurement
----------------------------------------

Patients were observed in the hospital for 7 days and followed up at D14, D21 and D28 for any symptoms or malaria parasites changes. Temperature was taken every six hours and once daily after it returned to normal(37.5°C) for 24 hours. Ward rounds were done twice daily in the morning and afternoon, and side effects were inquired and recorded according to the \"Side Effects Record Form\".

Thick and thin blood smears were taken at 7 AM and 5 PM from D0 to D4 to calculate the number of asexual form per 200 WBCs (White Blood Cells). If the number of parasites \< 1/200 WBC, 200 fields were examined to identify parasite clearance. Three consecutive negative blood smears (from D5 to D7) indicated clearance of parasite. For follow-ups, blood smears were taken at D14, D21 and D28 to investigate recrudescence. If a patient had fever, he or she was advised to go back to the hospital for further examination. Blood spots collected D0 and positive blood smears during 28-day follow up were kept for qualitative PCR analysis. Blood spots of patients whose blood smears were positive within 28-day follow up were sent to the Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam, for PCR qualitative analysis to differentiate re-infection and recrudescence.

WBC and RBC (Red Blood Cell) counts and electrocardiogram examination were done at D0 and D7. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), direct bilirubin (DBIL), creatinine (CR) and blood urea nitrogen(BUN)were also examined at D0 and D7. Abnormal items found at D7 were re-examined every week until the patient recovered.

The following four main efficacy parameters were used: Early Treatment Failure (ETF); Late Clinical Failure (LCF); Late Parasitological Failure (LPF); Adequate Clinical and Parasitological Response (ACPR) \[[@B18]\]. The occurrence rate of side effects (any symptoms and objective sign having appeared or aggravated after the administration) was recorded. Functions of liver and kidney and electrocardiogram before and after drug administration were checked in order to evaluate the toxicity and side effects of drug to the major organs.

Polymerase chain reaction (PCR)
-------------------------------

The patients in the trial continued to live in the area of transmission, therefore, re-infection during the four weeks of follow-up was possible. Then, PCR-genotyping were used to distinguish recrudescence from re-infection. Blood samples were taken at baseline (D0) and on the day of reappearance of parasitaemia \[[@B1]\]. The nested PCR of three polymorphic marker genes \[Merozoite Surface Antigen-1 (MSA-1), Merozoite Surface Antigen-1 (MSA-2), and Glutamine-rich Protein (GLURP)\] were conducted in University of Oxford Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam. PCR products were analyzed by agarose gel electrophoresis. Patients with the same parasite PCR profiles in the first and second infections were considered to have a recrudescent infection.

Statistical analysis
--------------------

Statistic analysis was conducted using SAS 6.12. Data were presented as means ± standard deviation (SD) or as the geometric mean and range. All statistical tests were two-tailed, and a significance level of 0.05 was used.

Ethical approval
----------------

The study was approved by the National Ethics Committee for Health Research of the Ministry of Health, Phnom Penh, Kingdom of Cambodia, and the Ethics Committee of Guangzhou University of Chinese Medicine, Guangzhou, China. This ethics approval of the trial describes recruitment of patients with uncomplicated infection with *P. falciparum*, with treatments for AP, DHP and AL, then research on the therapeutic efficacy and safety. The clinical trials registry number was 2005L01041.

Results
=======

Patient recruitment and participant flow
----------------------------------------

From 22 July, 2005 to 18 October, 2005, 220 patients completed in the study with 110 receiving AP, 55 receiving DHP and 55 receiving AL (Figure [1](#F1){ref-type="fig"}). Common reasons for exclusion included lack of follow-up data, and patients exiting before the 28-day follow up. Among the 220 patients completing the clinical trial, 18 (8.18%) were 7-10 years of age, 26 (11.82%) were 11-15 years of age, and 176 (80.00%) were more than 15 years old. A flow chart of patient enrollment procedures and treatment is shown in Figure [1](#F1){ref-type="fig"}. Baseline characteristics of the recruited patients are similar, and it is shown in Table [1](#T1){ref-type="table"}.

![**Patients flow chat in the clinical trial**.](1475-2875-10-231-1){#F1}

###### 

Patient age, symptoms, and other clinical measurements

  -----------------------------------------------------------------------------------------------------------------
  Characteristic                             Treatment arm                                              
  ------------------------------------------ ------------------- ------------------ ------------------- -----------
  **Number of patients**                     **AP**\             **DHP**\           **AL**\             **P**\
                                             **(n = 110)**       **(n = 55)**       **(n = 55)**        **value**

                                                                                                        

  Gender: Male/Female(ratio)                 72/28(2.57)         43/12(3.58)        46/9(5.11)          NS^a^

  Mean age, years(range)                     25.2(7-55)          21.9(8-64)         27.4(7-58)          NS

  Age Groups:                                                                                           

  7-10                                       11(10.0%)           2(3.6%)            5(9.1%)             NS

  11-15                                      16(14.54%)          5(9.1%)            5(9.1%)             NS

  \> 15                                      83(75.46%)          48(87.3%)          45(81.8%)           NS

  mean duration of fever (in days) (range)   4.2 (1.3-7.1)       4.6 (1.3-7.9)      5.3 (1.1-9.5)       NS

  Mean parasitaemia\                         26637(3801-49473)   25850(195-51505)   31297(1215-61379)   NS
  (1 ×/μl)(range)                                                                                       

  Body temperature (°C), mean (range)        38.5(37.7-39.3)     38.8 (37.7-39.9)   38.8(37.7-39.9)     NS

  Hepatomegly rate (%)                       5.5                 14.5               7.3                 NS

  Splenomegly rate (%)                       26.4                21.8               12.7                NS
  -----------------------------------------------------------------------------------------------------------------

NS: Not significant, P \> 0.05

Treatment effectiveness
-----------------------

There was no early treatment failure in the first three day following initiation of therapy for all the patients with 28-day follow up data. The Adequate Clinical and Parasitological Response (ACPR) of the three groups on D28 were 97/110 (88.2%), 54/55 (98.2) and 42/55 (76.4%), respectively (Table [2](#T2){ref-type="table"}). During the 28-day follow up, blood smears of 13 cases were found positive in the AP group. According to the results of PCR qualitative analysis, eight cases were classified as re-infection and five cases were recrudescence (one case recrudesced at D21 and four cases recrudesced at D28). In the DHP group, one blood smear was found positive at D28, and it was identified as recrudescence according to the qualitative PCR analysis. Among the 13 blood smear positive cases in the AL group, four cases were considered re-infection and nine cases were recrudescence (one case recrudesced at D14, three cases at D21 and five cases at D28).

###### 

Efficacy and parasite clearance time of the three treatment groups

  -------------------------------------------------------------------------------------------------------------------------------------
  Therapeutic response                             AP\                           DHP\                       AL\
                                                   (n = 110)                     (n = 55)                   (n = 55)
  ------------------------------------------------ ----------------------------- -------------------------- ---------------------------
  Excluded(%)                                      0                             0                          0

  Lost of follow-up (%)                            0                             0                          0

  Early Treatment Failure(%)                       0                             0                          0

  Late Clinical Failure(%, 95%CI)                  13(11.8, 5.79\~17.85%)        1(1.8, -1.71\~5.34%)       13(23.6,12.41\~34.86%)

  ACPR (%, 95% CI)\                                109 (99.1, 97.31\~100.86%)\   55(100, 93.6%\~100%)\      54(98.2, 94.65\~101.71%)\
  on D14\                                          105(95.5, 91.56%\~99.35%)\    55(100, 93.6%\~100%)\      48(87.3, 78.46%\~96.08%)\
  on D21\                                          97(88.2, 82.15%\~94.21%)      54(98.2, 94.65\~101.71%)   42(76.4, 65.14%\~87.59%)
  on D28                                                                                                    

  ACPR by Intention-to-treat analysis on D28 (%)   97/110\                       54/55\                     42/55\
                                                   (88.2)                        (98.2)                     (76.4)

  ACPR adjusted by PCR on D28\                     97/102\*^▲^\                  54/55\                     42/51\
  (%)                                              (95.1)                        (98.2)                     (82.4)

  Parasite clearance time, mean ± SD hours         66.7 ± 21.9\*^Δ^              65.6 ± 27.3^Δ^             65.3 ± 22.5

  Fever clearance time, mean ± SD hours            31.6 ± 17.7\*^Δ^              34.6 ± 21.8                36.9 ± 15.4
  -------------------------------------------------------------------------------------------------------------------------------------

Note: \*P \> 0.05, compared with DHP;^▲^P \< 0.05, compared with AL;^Δ^P \> 0.05, compared with AL.

The 28-day cure rates adjusted after PCR analysis were 97/102 (95.1%), 54/55(98.2%), 42/51 (82.4%) for AP, DHP and AL, respectively (Table [2](#T2){ref-type="table"}). There was no significant difference between AP and DHP (P \> 0.05). The 28-day cure rate in the AP group was significantly higher than that in the AL group (P \< 0.05) (Table [2](#T2){ref-type="table"}). The parasite and fever clearance time in the three groups were similar (P \> 0.05) (Table [2](#T2){ref-type="table"}).

Side effects
------------

There were no serious adverse events recorded during the trial. All of the three study drugs appeared to be well tolerated.

Haematology, electrocardiogram and biochemistry
-----------------------------------------------

No abnormal changes in haemotology and electrocardiogram were observed in the three study groups. Slightly increases in AST, ALT, BIL, BUN and CR measurements were found at D0 in all three groups, and most of them returned to normal ranges at D7. At D7, there were two cases with high TBIL in the AP group, one case with high AST and two cases with high CR, but they became normal at D14. There were four cases with high CR in the DHP group at D7; again they became normal at D14. There were two cases with high TBIL, three cases with high AST and one case with high BUN in the AL group at D7, and they returned normal at D14.

Discussion
==========

This randomized clinical trial showed that both AP and DHP were highly efficacious in clearing parasitaemia and were well tolerated for treatment of uncomplicated malaria in the Cambodia-Thailand border. Lower cure rate was obtained from AL treatment (Figure [2](#F2){ref-type="fig"}), which was similar to the results reported previously (71.1% cure rate in 2002 and 86.5% in 2003) \[[@B19]\]. The reason may be that, the lack of fat in the patient diet affected the absorption of lumefantrine, one of the partner drugs in AL. Dietary fat had been shown to enhance the bioavailability of artemether and lumefantrine, although this effect was more apparent for lumefantrine \[[@B13],[@B20],[@B21]\]. Administration of AL to healthy volunteers at the same time as a high-fat meal increases the bioavailability of artemether and lumefantrine by two-fold and 16-fold, respectively, compared with the fasting state \[[@B13],[@B21]\].

![**Survival curves**. (A new Kaplan Meier curve was added.). Recrudescence rate in each group was recorded on D0, D7, D14, D21, and D28, respectively, and further confirmed by PCR qualitative analysis.](1475-2875-10-231-2){#F2}

No obvious side effects related to the drugs were found in all the three groups. Although symptoms of anoxia, nausea, vomiting, headache and dizziness were observed in some patients, which was similar to those observed in Chinese healthy volunteers and in Vietnamese patients, as well as in Rwandan children \[[@B10],[@B22]-[@B26]\]. The occurrence rate of side effects was low. Comparing the results of haematology, biochemistry and electrocardiogram between those before and after drug administration showed no obvious toxic reactions related to drugs. The patients in the three groups had good tolerance to the drugs. Although more side effects caused by piperaquine phosphate in DHP than that by piperaquine base in AP combination were reported previously \[[@B27],[@B28]\], the data presented here did not show any differences in the two groups. In 1998, WHO launched Roll Back Malaria campaign, which aimed to reduce the global number of deaths due to malaria in half by 2010 \[[@B7]\]. However, until 2004, the global number of people having died of malaria had not declined, because the high prices of ACT have delayed timely drug distribution \[[@B16],[@B18]\]. In East Africa, failure rates of chloroquine and sulphadoxine-pyrimethamine treatment were 64% and 45%, respectively, and children deaths due to malaria increased by 11-fold \[[@B8],[@B29]\]. Therefore, it is imminent to develop affordable ACT, that is cheaper for people in malaria-endemic countries.

The 28-day cure rate of AP for uncomplicated falciparum malaria was high, the patients had good tolerance to AP as shown above, and by taking four tablets as the total dosage for adults over a 24-hour treatment was convenient and help to improve patients\' compliance. Hence, this dosage was recommended for the expanding clinical trial (Phase III).

Conclusions
===========

In this study, three different forms of ACTs (AP, DHP and AL) were compared in the multi-drug resistant falciparum malaria epidemic areas in the Cambodia-Thailand border.

The data from this report demonstrated that the AP regimen turned out to be favourable in terms of efficacy and effectiveness, simplicity of administration, cost and compliance in this particular setting, and it might play an important role for malaria control in the near future.
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